Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Single arm study with dose escalation Phase Ib cohort followed by a Phase II cohort. PAC-1
(PO) will be given daily on Days 1 through 21 of each cycle (28-day cycle). Entrectinib (PO)
will be given daily on Days 1 through 28 of each cycle. Response will be evaluated after
every 2 cycles. Treatment will continue until disease progression based on RECIST criteria or
intolerable toxicity.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Arkadiusz Z. Dudek, MD
Collaborators:
Genentech, Inc. HealthPartners Regions Cancer Care and Frauenshuh Cancer Care Centers Midwest Melanoma Partnership Vanquish Oncology, Inc.